COST-EFFECTIVENESS ANALYSIS OF CEFTRIAXONE-AZITHROMYCIN COMBINATION AND SINGLE LEVOFLOXACIN AS EMPIRICAL ANTIBIOTICS IN COMMUNITY-ACQUIRED PNEUMONIA INPATIENTS AT PERSAHABATAN HOSPITAL
DOI:
https://doi.org/10.22159/ajpcr.2017.v10s5.23112Keywords:
Cost-effectiveness, Antibiotic, Community-acquired pneumonia, Ceftriaxone, Azithromycin, LevofloxacinAbstract
Â
 Objective: Community-acquired pneumonia (CAP) is one of the most common infectious diseases. Its prevalence is especially concerning, as the disease severely impacts health and has a high mortality rate. Although antibiotics have been used to treat CAP, their use is often costly and inefficient. Thus, this study aimed to determine the cost-effectiveness of using ceftriaxone-azithromycin combination and single levofloxacin as empirical antibiotics to treat patients with CAP. Cost-effectiveness was analyzed by comparing the direct total medical cost to clinical effectiveness, which was indicated by the respective success rates in each treatment group.
Methods: This study was conducted at Persahabatan Hospital in Jakarta and employed an observational study design, where data were obtained retrospectively from the secondary data contained in medical records for 2014-2016. A total of 100 patients were included in the analysis, with 64 patients using intravenous (iv) antibiotic ceftriaxone and oral azithromycin and 36 patients using iv single levofloxacin.
Results: The median costs of antibiotics were significantly different between the ceftriaxone-azithromycin group and the levofloxacin group: Rp.130.756 and Rp.286.952, respectively. The direct total medical cost in the ceftriaxone-azithromycin group (Rp.6.494.998) was higher than that of the single levofloxacin group (Rp.5.444.242). The success rate was 95.3% in the ceftriaxone-azithromycin group and 97.2% in the levofloxacin group, but there were no significant differences between the two groups. The medians for the length of stay (LOS) and length of stay antibiotic-related (LOSAR) measures in the levofloxacin group were 6 and 5 days, which were shorter than the LOS and LOSAR medians in the ceftriaxone-azithromycin group: 7 days and 6 days, respectively. The average cost-effectiveness ratio value in the levofloxacin group was 56.011% effectiveness lower than that of the ceftriaxone-azithromycin group, which was Rp.68.153% effectiveness.
Conclusions: Based on these results, it can be concluded that levofloxacin is more cost-effective than a combination of ceftriaxone-azithromycin for treating CAP.
Downloads
References
Menendez R, Reyes S, Martinez R, de la Cuadra P, Valles JM, Vallterra J. Economic evaluation of adherence to treatment guidelines in non-intensive care pneumonia. Eur Respir J 2007;29:751-6.
Alldredge K, Corelli RL, Ernst ME. Applied Therapeutics, the Clinical use of Drugs. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013.
Vigg A. Severe community acquired pneumonia (SCAP). Apollo Med 2016;13(1):17-9.
Indonesian Pulmonologist Association. Pneumonia Komunitas. Jakarta: Pedoman Diagnosis dan Penatalaksanaan di Indonesia; 2014.
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 Suppl 2:S27-72.
Bhavnani SM, Ambrose PG. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/ without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. Diagn Microbiol Infect Dis 2008;60(1):59-64.
Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 2001;119(5):1439-48.
Shea KM, Weycker D, Stevenson AE, Strutton DR, Pelton SI. Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US. Vaccine 2011;29(45):8042-8.
Rozenbaum MH, Mangen MJ, Huijts SM, van der Werf TS, Postma MJ. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis. Vaccine 2015;33(28):3193-9.
Sato R, Gomez Rey G, Nelson S, Pinsky B. Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged=50 years. Appl Health Econ Health Policy 2013;11(3):251-8.
Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: A literature review. Thorax 2013;68(11):1057-65.
González-Castillo J, MartÃn-Sánchez FJ, Llinares P, Menéndez R, Mujal A, Navas E, et al. Guidelines for the management of community-acquired pneumonia in the elderly patient. Rev Esp Quimioter 2014;27(1):69-86.
Indonesian Ministry of Health. Basic Health Survey. Mumbai: Indonesian Ministry of Health; 2013.
Skalsky K, Yahav D, Lador A, Eliakim-Raz N, Leibovici L, Paul M. Macrolides versus quinolones for community-acquired pneumonia: Meta-analysis of randomized controlled trials. Clin Microbiol Infect 2012;19(4):370-8.
Andayani TM. Farmakoekonomi Prinsip dan Metodologi. Yogyakarta: Bursa Ilmu; 2013.
Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 2007;51(11):3977-82.
Querol-Ribelles JM, TenÃas JM, Querol-Borrás JM, Labrador T, Nieto A, González-Granda D, et al. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization. Int J Antimicrob Agents 2005;25(1):75-83.
Vardakas KZ, Siempos II, Grammatikos A, Athanassa Z, Korbila IP, Falagas ME. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: A meta-analysis of randomized controlled trials. CMAJ 2008;179(12):1269-77.
Menéndez R, Cremades MJ, MartÃnez-Moragón E, Soler JJ, Reyes S, Perpiñá M. Duration of length of stay in pneumonia: Influence of clinical factors and hospital type. Eur Respir J 2003;22(4):643-8.
Garau J, Baquero F, Pérez-Trallero E, Pérez JL, MartÃn-Sánchez AM, GarcÃa-Rey C, et al. Factors impacting on length of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect 2008;14:322-9.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.